YOLFTbeta
68

Sinotherapeutics Inc. A

688247 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

7.95CNY-0.27 (-3.28%)

Price History

Full chart

Market Stats

Previous Close8.22
Open8.30
Day Range7.81 – 8.46
52-Week Range7.02 – 11.44
Volume8.18M
Market Cap4.57B
P/E (TTM)126.13
Forward P/E0.00
EPS0.08
Dividend Yield0.35%
Beta0.10
50-Day Avg9.27
200-Day Avg9.39

About

Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride sustained-release tablets, and ursodeoxycholic ACID Capsules. The company also provides bupropion hydrochloride extended-release tablets, and paroxetine and pregabalin extended-release tablets; propafenone hydrochloride extended-release capsules; and sevelamer carbonate tablets. Sinotherapeutics Inc. was founded in 2012 and is headquartered in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Ming Jie Guo
  • Employees319
  • Headquarters99 Haike Road, Shanghai, China, 201210, China
  • Websitehttps://www.sinotph.com

Leadership

  • Mr. Ming Jie GuoGeneral Manager · b. 1973
  • Ms. Pei Hua WeiAccounting Supervisor · b. 1976
  • Mr. Fang Li LiDeputy GM & Secretary · b. 1990
  • Mr. Kun LiDeputy General Manager · b. 1982
  • Ms. Jian Hong LinDeputy General Manager · b. 1977

Financials

Income Statement

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue319.16M315.47M247.56M299.87M511.62M446.57M
Growth (%)--1.16%-21.53%+21.13%+70.61%-12.71%
Cost of Revenue58.97M69.00M71.23M132.26M247.47M270.54M
Gross Profit260.18M246.47M176.34M167.61M264.15M176.03M
Gross Margin81.52%78.13%71.23%55.89%51.63%39.42%
Operating Expense128.36M126.22M108.80M114.95M136.34M114.50M
Operating Income131.82M120.25M67.54M52.66M127.81M61.52M
Operating Margin41.30%38.12%27.28%17.56%24.98%13.78%
EBITDA--124.12M89.30M166.92M85.24M
EBITDA Margin--50.13%29.78%32.62%19.09%
Net Income123.30M134.92M92.93M61.07M127.70M47.48M
Net Income Margin38.63%42.77%37.54%20.37%24.96%10.63%
R&D75.80M103.63M76.02M74.01M84.92M74.94M
R&D as % of Total Revenue23.75%32.85%30.71%24.68%16.60%16.78%
Interest Expense-229.69K213.52K37.81K2.55K1.41K
Interest Expense % of Total Revenue-0.07%0.09%0.01%0.00%0.00%

Balance Sheet

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets743.14M865.81M1.33B1.36B1.45B1.44B
Total Liabilities180.76M160.62M155.05M151.36M180.30M146.12M
Total Equity562.38M705.19M1.18B1.21B1.27B1.29B
Cash434.17M511.65M763.15M641.78M225.79M407.11M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-210.04M145.77M73.18M12.96M130.23M95.33M
Capital Expenditure038.34M16.01M176.34M38.96M94.93M41.56M
Free Cash Flow-171.70M129.77M-103.15M-26.00M35.30M53.77M
Dividends Paid----28.11M27.88M27.84M
FCF to OCF-81.75%89.02%-140.95%-200.63%27.10%56.40%
Dividend Paid to FCF-----108.11%78.98%51.78%

Earnings

Report DateSep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate---
EPS Actual0.060.060.02
Surprise---
Timing---

Key Statistics & Ratios

Market Cap4.57B
Enterprise Value3.83B
Trailing P/E126.13
Forward P/E0.00
Price / Sales10.94
Price / Book3.52
EPS0.08
Book Value2.94
Revenue (TTM)418.12M
Gross Profit (TTM)149.65M
EBITDA39.59M
Profit Margin7.56%
Operating Margin7.57%
Return on Equity2.41%
Return on Assets0.63%
Shares Outstanding453.34M
Shares Float109.49M
Beta0.10
Dividend Yield0.35%
Dividend Rate0.04
Payout Ratio43.75%

Dividends

20262×
0.01Oct 23, 20260.01Jun 26, 2026
20252×
0.03Oct 21, 20250.04Jun 27, 2025
20242×
0.03Oct 25, 20240.04Jun 28, 2024
20231×
0.06Jul 7, 2023